New therapies for treating Down syndrome require quality of life measurement

  title={New therapies for treating Down syndrome require quality of life measurement},
  author={Michael J. Goodman and Diana I. Brixner},
  journal={American Journal of Medical Genetics Part A},
Down syndrome (DS) is the most common genetic cause of cognitive deficits. Using mouse models and therapies for Alzheimer disease, researchers are exploring therapies that may improve cognitive function in people with DS. These developments shift the health economic paradigm of understanding DS from determining the appropriate screening tool to the effect of therapy on quality of life in those with DS. To date, there are no validated quality of life instruments for DS. Research should begin to… 
There are several suggestions that assessing quality of life (QoL) in people with Down syndrome (DS) could be desirable for clinical, scientific, economic reasons and beyond. The aim of the present
Personalized Management of Selected Neurological Disorders
This chapter discusses research, as well as current opportunities and future prospects towards personalized medicine in relation to selected neurological disorders and diseases such as Down syndrome, neuronal ceroid lipofuscinoses (NCLs), and multiple sclerosis (MS).
Down Syndrome and Quality of Life: A Case Report
Therapies targeting cognition could result in the maintenance of quality of life and, ultimately, lower health care costs.
Cost-effectiveness analysis for triple markers serum screening for Down's syndrome in Thai setting
The author analyzes and presents the cost-effectiveness of the triple markers serum screening for Down's syndrome in Thai setting and finds that the cost per effectiveness is slightly lower than standard amniocentesis test.
Vision problems in Down syndrome adults do not hamper communication, daily living skills and socialisation
Effective early correction and intervention on visual-motor deficits seem to be important, but nevertheless personal autonomy is not seriously detained.
Health-related Quality of Life (HR-QOL) and Chronic Health Conditions in Survivors of Childhood Acute Myeloid Leukemia (AML) with Down Syndrome (DS): A Report From the Children’s Oncology Group
mean physical and psychosocial QOL scores for children with DS and AML were statistically lower than the population mean, though not discrepant from AML survivors without DS, suggesting that AML therapy may not substantially increase this risk.
Quality of health care according to people with Down syndrome, their parents and support staff—A qualitative exploration
The findings of this study may be used to improve health care for PDS, and provide insight into how health care could match the specific needs of PDS.
Adapting a Measure of Quality of Life to Children with Down Syndrome for the Development of Evidence-based Interventions
espanolRESUMEN La investigacion ha puesto de manifiesto que actualmente no existen instrumentos que presenten una adecuada evidencia de validez y fiabilidad para evaluar la calidad de vida (CV) de
Gajra Raja Medical College, Madhya Pradesh, India
Background: Melanoma is a malignant skin cancer and is one of the most aggressive malignancies in humans. Heavy metals, including lead, are known to cause cellular toxicity and have been studied for


Down syndrome and Alzheimer disease: response to donepezil.
Significant improvement in dementia scores for the treated group during a 3- to 5-month period supports the rationale for a more extensive study of the efficacy of acetylcholinesterase inhibitors in Down syndrome dementia.
Donepezil Significantly Improves Abilities in Daily Lives of Female down Syndrome Patients with Severe Cognitive Impairment: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial
Donepezil may effectively and safely improve overall functioning of DS patients with severe cognitive impairment and there was a dramatic improvement in the global mental functions and in specific mental functions.
Donepezil for the treatment of language deficits in adults with Down syndrome: A preliminary 24‐week open trial
The main finding that emerged was an improvement in expressive language performance following donepezil therapy, which supports the need for large‐scale controlled studies of the effects ofdonepezil treatment on language and on other cognitive domains in DS.
Safety and efficacy of rivastigmine in adolescents with Down syndrome: a preliminary 20-week, open-label study.
Improved language performance was found across all functional levels and the need for larger, controlled studies employing a carefully constructed test battery capable of measuring the full scope of performance across multiple domains and a wide range of functional levels is underscore.
Pharmacotherapy for cognitive impairment in a mouse model of Down syndrome
It is shown that chronic systemic treatment of Ts65Dn mice with GABAA antagonists at non-epileptic doses causes a persistent post-drug recovery of cognition and long-term potentiation, suggesting that over-inhibition contributes to intellectual disabilities associated with Down syndrome.
Donepezil for treatment of cognitive dysfunction in children with Down syndrome aged 10–17
This trial failed to demonstrate any benefit for donepezil versus placebo in children and adolescents with DS, although didpezil appeared to be well tolerated.
Effects of donepezil on cognitive functioning in Down syndrome.
The results suggest that donepezil may improve language performance in subjects with Down syndrome and no dementia, but further studies need to be done on a larger group to confirm this result.
Dramatic Improvement in down Syndrome—Associated Cognitive Impairment with Donepezil
Donepezil may be a useful medicine for some patients with Down syndrome with severe cognitive impairment or mental retardation if the adverse effects are manageable, although they may also have adverse effects more frequently.
Memantine for dementia in adults older than 40 years with Down's syndrome (MEADOWS): a randomised, double-blind, placebo-controlled trial
Both groups declined in cognition and function but rates did not differ between groups for any outcomes, and Therapies that are effective for Alzheimer's disease are not necessarily effective in this group of patients.
Preliminary study of the safety and efficacy of donepezil hydrochloride in children with Down syndrome: A clinical report series
Preliminary safety and cognitive efficacy data for seven children with Down syndrome who participated in a 22‐week, open‐label trial of donepezil hydrochloride support the need for larger, double‐blind studies of the safety and efficacy ofdonepezil and other cholinesterase inhibitors for children with DS.